These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 36558842)

  • 1. Cefiderocol against Multi-Drug and Extensively Drug-Resistant
    Zalas-Więcek P; Płachta K; Gospodarek-Komkowska E
    Pathogens; 2022 Dec; 11(12):. PubMed ID: 36558842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of In Vitro Activity of Cefiderocol Against Carbapenem-Resistant Gram-Negative Bacilli by Broth Microdilution and Disk Diffusion Method: A Single-Center Study in Odisha, India.
    Nayak G; Behera B; Mohanty S; Kar P; Jena J
    Infect Drug Resist; 2022; 15():5887-5897. PubMed ID: 36237292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefiderocol: An Overview of Its
    Yao J; Wang J; Chen M; Cai Y
    Front Med (Lausanne); 2021; 8():741940. PubMed ID: 34950677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014).
    Kohira N; Hackel MA; Ishioka Y; Kuroiwa M; Sahm DF; Sato T; Maki H; Yamano Y
    J Glob Antimicrob Resist; 2020 Sep; 22():738-741. PubMed ID: 32702396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High efficacy and enhanced synergistic activity of the novel siderophore-cephalosporin cefiderocol against multidrug-resistant and extensively drug-resistant Klebsiella pneumoniae from inpatients attending a single hospital in the United Arab Emirates.
    Daoud L; Al-Marzooq F; Ghazawi A; Anes F; Collyns T
    J Infect Public Health; 2023 Dec; 16 Suppl 1():33-44. PubMed ID: 37953111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
    Bianco G; Boattini M; Comini S; Iannaccone M; Bondi A; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):63-70. PubMed ID: 34462816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterisation of cefiderocol-non-susceptible Acinetobacter baumannii isolates from Taiwan.
    Yamano Y; Ishibashi N; Kuroiwa M; Takemura M; Sheng WH; Hsueh PR
    J Glob Antimicrob Resist; 2022 Mar; 28():120-124. PubMed ID: 34958997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region.
    Johnston BD; Thuras P; Porter SB; Anacker M; VonBank B; Snippes Vagnone P; Witwer M; Castanheira M; Johnson JR
    Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32718965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antibacterial activities of cefiderocol against Gram-negative clinical strains isolated from China in 2020.
    Kohira N; Hackel MA; Oota M; Takemura M; Hu F; Mizuno H; Sahm DF; Yamano Y
    J Glob Antimicrob Resist; 2023 Mar; 32():181-186. PubMed ID: 36513320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
    Bianco G; Boattini M; Comini S; Casale R; Iannaccone M; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):573-580. PubMed ID: 35061145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium.
    Oueslati S; Bogaerts P; Dortet L; Bernabeu S; Ben Lakhal H; Longshaw C; Glupczynski Y; Naas T
    Antibiotics (Basel); 2022 Oct; 11(10):. PubMed ID: 36290010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to Cefiderocol Involved Expression of PER-1 β-Lactamase and Downregulation of Iron Transporter System in Carbapenem-Resistant
    He Y; Wang Y; Ma X; Zhao L; Guan J; Zhao J; Yu W; Li Y; Ni W; Gao Z
    Infect Drug Resist; 2022; 15():7177-7187. PubMed ID: 36514799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vitro Susceptibility of
    Jena J; Behera B; Nayak G; Mohanty S; Mahapatra A; Purushotham P; Radhakrishnan A; Tripathy M
    J Lab Physicians; 2023 Dec; 15(4):573-577. PubMed ID: 37780886
    [No Abstract]   [Full Text] [Related]  

  • 16. Elucidating the effect of iron acquisition systems in Klebsiella pneumoniae on susceptibility to the novel siderophore-cephalosporin cefiderocol.
    Daoud L; Al-Marzooq F; Moubareck CA; Ghazawi A; Collyns T
    PLoS One; 2022; 17(12):e0277946. PubMed ID: 36580460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
    Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
    Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in U.S. Medical Centers, 2011 to 2015.
    Sader HS; Castanheira M; Flamm RK
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28069649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
    Juan C; Zamorano L; Pérez JL; Ge Y; Oliver A; ;
    Antimicrob Agents Chemother; 2010 Feb; 54(2):846-51. PubMed ID: 19933793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.